Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06820307 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06820307 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 50 participants.
The verdict
NCT06820307, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of SUZ on the pharmacokinetics of oral contraceptives.
Interventions
- DRUG Suzetrigine
- DRUG NGM/EE
- DRUG DRSP/EE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2025-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06820307
The ClinicalTrials.gov registry entry for NCT06820307 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Suzetrigine is the first listed.
NCT06820307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06820307 about?
NCT06820307 is a clinical study titled "Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants". The purpose of this study is to evaluate the effect of SUZ on the pharmacokinetics of oral contraceptives.
What is the current status of trial NCT06820307?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-02-25. Estimated completion is 2025-04-29.
What interventions are being tested in trial NCT06820307?
The interventions under investigation include: Suzetrigine (DRUG), NGM/EE (DRUG), DRSP/EE (DRUG).
Who is sponsoring clinical trial NCT06820307?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.